In particular, myasthenia gravis is considered an emerging side effect of immunotherapies (32), and in the literature, there are many case reports that consider myasthenia as a possible complication of anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy (2, 30, 31, 33–37). Here, CTLA4 is linked to Fatigable weakness.